Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
HIV-1 envelope glycoprotein-mediated fusion is driven by the concerted coalescence of the HIV-1 gp41 N-and C-helical regions, which results in the formation of 6-helix bundles. These two regions are considered prime targets for peptides and antibodies that inhibit HIV-1 entry. However, the parameters that govern this inhibition have yet to be elucidated. We address this issue by monitoring the temporal sequence of conformational states of HIV-1 gp41 during the course of HIV-1-mediated cell-cell fusion by quantitative video microscopy using reagents that bind to N-and C-helical regions, respectively. Env-expressing cells were primed by incubation with target cells at different times at 37 °C followed by washing. The reactivity of triggered gp41 to the NC-1 monoclonal antibody, which we demonstrate here to bind to N-helical gp41 trimers, increased rapidly to a maximal level in the primed state but decreased once stable fusion junctions had formed. In contrast, reactivity with 5-helix, which binds to the C-helical region of gp41, increased continuously as a function of time following the priming. The peptide N36 Mut(e,g) reduced NC-1 monoclonal antibody binding and enhanced 5-helix binding, consistent with the notion that this molecule promotes dissociation of gp41 trimers. This inactivation pathway may be important for the design of entry inhibitors and vaccine candidates.Membrane fusion mediated by human immunodeficiency virus (HIV)-1 1 envelope glycoproteins (gp120-gp41) is a critical step in the entry of the virus into susceptible cells (1). The current model of HIV viral entry involves the binding of the trimeric viral envelope glycoprotein gp120/gp41 to cell-surface receptor CD4 and chemokine coreceptor CXCR4 or CCR5 (2, 3), which triggers conformational changes in the envelope proteins (4). gp120 then disengages from gp41, allowing for the fusion peptide to be inserted into the target membrane and the prehairpin configuration of the ectodomain to form (5-7). The C-terminal heptad repeat region (C-helical region) and the leucine/isoleucine zipper region (N-helical region) 2 1 Abbreviations: HIV, human immunodeficiency virus; DMEM, Dulbecco's modified Eagle medium; CHO, Chinese hamster ovary; Cy5, N,; PBS, phosphate-buffered saline; D-PBS, Dulbecco's PBS; CMAC, Tricine,glycine. 2 For convenience, we use the notation N-and C-helical regions or peptides, although they only become α-helical when associated as homo-or heterotrimers. NIH Public Access NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author Manuscript the thermostable 6-helix bundle (8-11), which drives the membrane merger and eventual fusion (12). In addition to structural information, a wealth of HIV Env-mediated fusion data, which includes inhibition by peptides that mimic the sequences of the N-and C-helical regions (13-21) and fusion kinetics (22), has lent credence to this model. In the absence of complete structural information, some of the details of the HIV-1 Env-mediated fusion reaction have been inferred from immunochemi...
HIV-1 envelope glycoprotein-mediated fusion is driven by the concerted coalescence of the HIV-1 gp41 N-and C-helical regions, which results in the formation of 6-helix bundles. These two regions are considered prime targets for peptides and antibodies that inhibit HIV-1 entry. However, the parameters that govern this inhibition have yet to be elucidated. We address this issue by monitoring the temporal sequence of conformational states of HIV-1 gp41 during the course of HIV-1-mediated cell-cell fusion by quantitative video microscopy using reagents that bind to N-and C-helical regions, respectively. Env-expressing cells were primed by incubation with target cells at different times at 37 °C followed by washing. The reactivity of triggered gp41 to the NC-1 monoclonal antibody, which we demonstrate here to bind to N-helical gp41 trimers, increased rapidly to a maximal level in the primed state but decreased once stable fusion junctions had formed. In contrast, reactivity with 5-helix, which binds to the C-helical region of gp41, increased continuously as a function of time following the priming. The peptide N36 Mut(e,g) reduced NC-1 monoclonal antibody binding and enhanced 5-helix binding, consistent with the notion that this molecule promotes dissociation of gp41 trimers. This inactivation pathway may be important for the design of entry inhibitors and vaccine candidates.Membrane fusion mediated by human immunodeficiency virus (HIV)-1 1 envelope glycoproteins (gp120-gp41) is a critical step in the entry of the virus into susceptible cells (1). The current model of HIV viral entry involves the binding of the trimeric viral envelope glycoprotein gp120/gp41 to cell-surface receptor CD4 and chemokine coreceptor CXCR4 or CCR5 (2, 3), which triggers conformational changes in the envelope proteins (4). gp120 then disengages from gp41, allowing for the fusion peptide to be inserted into the target membrane and the prehairpin configuration of the ectodomain to form (5-7). The C-terminal heptad repeat region (C-helical region) and the leucine/isoleucine zipper region (N-helical region) 2 1 Abbreviations: HIV, human immunodeficiency virus; DMEM, Dulbecco's modified Eagle medium; CHO, Chinese hamster ovary; Cy5, N,; PBS, phosphate-buffered saline; D-PBS, Dulbecco's PBS; CMAC, Tricine,glycine. 2 For convenience, we use the notation N-and C-helical regions or peptides, although they only become α-helical when associated as homo-or heterotrimers. NIH Public Access NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author Manuscript the thermostable 6-helix bundle (8-11), which drives the membrane merger and eventual fusion (12). In addition to structural information, a wealth of HIV Env-mediated fusion data, which includes inhibition by peptides that mimic the sequences of the N-and C-helical regions (13-21) and fusion kinetics (22), has lent credence to this model. In the absence of complete structural information, some of the details of the HIV-1 Env-mediated fusion reaction have been inferred from immunochemi...
The end of the twentieth century saw dramatic improvements in the prognosis of HIV infection brought about by the introduction of new agents (the protease inhibitors and the non-nucleoside reverse transcriptase inhibitors) and their use in highly active combinations. However, the durability of these combination treatments is limited by a number of factors including adverse effects and extensive intra-class cross-resistance so that new antiretrovirals acting on alternative targets and having improved systemic tolerability profiles are required. The HIV binding and entry process offers several potential targets for antiviral interaction. These include gp120 binding to CD4 and to chemokine co-receptor molecules as well as the fusion process itself, which involves interactions between two leucine zipper-like 4-3 repeat regions within gp41 known as heptad repeat (HR)1 and HR2. Peptides such as enfuvirtide (formerly DP178 or T-20), that mimic the HR2 region of gp41, inhibit HIV-1 by a mechanism that is thought to involve competitive binding to HR1. This review summarises the clinical development of enfuvirtide, providing an overview of the pharmacokinetic, efficacy and safety data in various patient populations, and also considers the evidence for the key role of genotypic changes in the HR1 region (amino acids 36-45) in determining viral susceptibility to inhibition by enfuvirtide.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.